Eckert & Ziegler Strahlen- und Medizintechnik AG / DE0005659700
14.11.2023 - 07:45:09Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
| Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figures Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023 14.11.2023 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 14 November 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month result was around € 2 million higher than the previous year's figure. In addition, there was an increase in expenses for future projects in the field of nuclear medicine diagnostics and therapy. In the Medical segment, sales of € 82.8 million were around € 17.6 million or 27% higher than in the previous year. The main growth driver continues to be business with pharmaceutical radioisotopes, while sales of laboratory equipment and in the plant engineering division also continued to increase. At € 101.0 million, the Isotope Products segment generated slightly higher external sales of € 0.5 million than in the first nine months of 2022. The segment's sales thus remained stable. The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of around € 230 million and net income of around € 25 million. The complete quarterly report can be viewed here: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz323e.pdf About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse. Contributing to saving lives. Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 14.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1772143 |
| End of News | EQS News Service |
| |
